Myricx Bio Expands Board with Notable Appointment
Myricx Bio, a cutting-edge biotech firm specializing in innovative cancer therapies, has announced the appointment of Dr. Paolo Paoletti, MD, to its Board of Directors as an Independent Non-Executive Director. This strategic addition is part of Myricx's ongoing efforts to enhance its leadership team and further develop its innovative products aimed at treating cancer.
Dr. Paolo Paoletti's Extensive Background
Dr. Paoletti joins Myricx with a wealth of experience in the life sciences sector. His remarkable track record includes serving as the first President of GSK’s Oncology division. Over his tenure, he successfully launched seven new cancer treatments focused on precision medicine, significantly improving patient outcomes. Notably, he played a vital role in a landmark acquisition when GSK's Oncology Franchise was sold to Novartis for a staggering $16 billion.
Leadership and Achievements in Biotech
Prior to joining Myricx, Dr. Paoletti held the CEO position at GammaDelta Therapeutics. Under his leadership, the company developed Vdelta1 Gammadelta T cells, advancing them through to clinical stages before being acquired by Takeda in 2022. Additionally, Dr. Paoletti has held key roles at Eli Lilly, showcasing a rich background in pharmaceutical development.
Contributions to Academia and Research
Dr. Paoletti's contribution to the academic world is impressive; he has authored over 300 publications and has held prestigious positions, including Professor of Pulmonary Medicine at the University of Pisa. His deep understanding of medical science and commitment to research bolster Myricx's mission.
Myricx Bio's Vision for the Future
In recent months, Myricx Bio has successfully secured £90 million ($114 million) in a Series A financing round, allowing for an expansion of its team and relocation to new facilities within the London Innovation Centre. This infusion of capital will support the acceleration of their unique antibody-drug conjugates (ADCs) that utilize inhibitors of N-Myristoyltransferases (NMT). This pipeline holds great potential for addressing significant unmet needs in oncology.
Important Statements from Leadership
Chris Martin, the Chairman of Myricx Bio, expressed his enthusiasm for Dr. Paoletti’s appointment, stating, "I am delighted to welcome Paolo to the board. He brings extensive leadership experience in R&D and commercialization in the pharma and biotech industry, which will be invaluable as we advance our NMTi ADCs towards clinical development." This sentiment underscores the commitment of Myricx to foster an inclusive and visionary leadership team.
The Science Behind Myricx Bio's Innovations
At its core, Myricx Bio focuses on developing therapies based on inhibitors of N-Myristoyltransferases – enzymes that play a crucial role in the survival of cancer cells. Their ADC platform aims to combine a novel class of payloads with antibodies to create highly targeted therapies that can potentially improve treatment outcomes for patients suffering from various cancers.
Global Impact and Partnerships
As a spinout of Imperial College London and the Francis Crick Institute, Myricx Bio has a solid foundation in research and innovation. The company has garnered support from notable investors, including Abingworth, Brandon Capital Partners, and Novo Holdings. This backing strengthens their ability to advance groundbreaking treatments that could transform cancer care globally.
Future Directions and Innovations
Myricx is determined to continue its momentum in research and clinical development, with a strong focus on creating therapies that address severe cancer types effectively. With the innovative background and expertise of its newly appointed board member, the company is well-positioned to push boundaries within the oncology sector.
Frequently Asked Questions
Who is Dr. Paolo Paoletti?
Dr. Paolo Paoletti is a renowned leader in the biotech field with extensive experience in oncology, including senior roles in leading pharmaceutical companies.
What is Myricx Bio's main focus?
Myricx Bio specializes in the discovery and development of novel payloads for antibody-drug conjugates aimed at treating cancer.
What recent advancements has Myricx Bio made?
Recently, Myricx Bio secured £90 million in funding to expand its team and enhance research facilities aimed at advancing its therapeutic pipeline.
How does Myricx Bio's ADC technology work?
Myricx Bio's ADC technology utilizes inhibitors of N-Myristoyltransferases to develop targeted therapies that can effectively kill cancer cells while minimizing damage to healthy tissue.
How can I contact Myricx Bio for more information?
For inquiries, you can reach out to Dr. Robin Carr, CEO, at info@myricxbio.com or through media inquiries to Sue Charles at sue@charles-consultants.com.
